Musi waChikunguru 27, 2023, Lilly akazivisa kuti ongororo yeMount-3 yeTirzepatide yekurapa varwere vakafuta uye yeMount-4 kudzidza kuchengetedza uremu hwevarwere vakafutisa yakanga yasvika padanho rekutanga uye kiyi yechipiri yekupedzisira.Iyi ndiyo yechitatu neyechina yakabudirira chikamu III tsvakiridzo yakawanikwa neTirzepatide mushure meGomo-1 neGomo-2.
SURMOUNT-3 (NCT04657016) muedzo wakawanda, wakasarudzika, wakapetwa kaviri, wakafanana, wakadzorwa neplacebo unonyoresa huwandu hwevatori vechikamu 806 hwakagadzirirwa kuratidza hukuru hweTirzepatide pamusoro pe placebo maererano nehuwandu hwekuchinja kwehuremu mushure mekusarongeka uye muzana ye vatori vechikamu vakarasikirwa ≥5% mushure mekuita randomization pamasvondo e72.
Iyo SURMOUNT-3 yeongororo yemhedzisiro yakaratidza kuti Tirzepatide yakasangana nemagumo ese, kureva kuti mushure memavhiki makumi manomwe nemaviri ekurapa dosing, varwere vari muboka reTirzepatide vakawana chikamu chepamusoro chekurasikirwa nehuremu kubva pakutanga zvichienzaniswa ne placebo, uye chikamu chepamusoro chevarwere muboka reTirzepatide. vakawana uremu huremu hunodarika 5%.Yakananga kliniki data yakaratidza kuti varwere vanobatwa neTirzepatide vakarasikirwa neavhareji ye21.1% yehuremu hwemuviri kana ichienzaniswa ne placebo;Yakasanganiswa ne12-vhiki yekupindira nguva, varwere vanobatwa neTirzepatide vakarasikirwa neavhareji ye26.6 muzana yehuremu hwemuviri wavo.Mukuwedzera, 94.4% yevarwere vakarasikirwa ≥5% yehuremu hwavo muboka reTirzepatide, zvichienzaniswa ne10.7% muboka re placebo.
SURMOUNT-4 (NCT04660643) muyedzo wakawanda, wakasarudzika, wakapetwa kaviri, wakafanana, wakadzorwa neplacebo unonyoresa huwandu hwevatori vechikamu 783 hwakagadzirirwa kuratidza kuti Tirzepatide yaive yepamusoro pane placebo muhuwandu hwekuchinja kwehuremu pa88-vhiki randomization.
Zvigumisiro zvakaratidza kuti mushure memazuva maviri-mapofu emavhiki e37 ~ 88, varwere vari muboka reTirzepatide vakarasikirwa nehuremu kupfuura muboka re placebo.Panyaya yekuchengeteka, hapana SURMOUNT-3 kana SURMOUNT-4 zvidzidzo zvakaona zviratidzo zvitsva zvekuchengetedza.
Kubva pakatangwa Novo Nordisk's blockbuster diet drug Semaglutide, pamwe chete neMusk's endorsement, yave chinhu chinoshamisa cheInternet mukurumbira chigadzirwa uye iyezvino uremu huremu mambo.Musika wekurasikirwa uremu unodiwa wakakura, uye kune maviri chete GLP-1 uremu mishonga pari zvino pamusika, Liraglutide uye Semaglutide, asi Liraglutide gadziriro yenguva pfupi, isingakwanise kukwikwidza nekugadzirira kwenguva refu maererano nekuteerera kwemurwere. , uye nyika yazvino yekurasikirwa kwepasi kwenguva pfupi ndeyeSemaglutide.
Zvakare mambo wemunda weGLP-1, Lilly anochiva gungwa rebhuruu remusika wekurasikirwa nehuremu - saka Lilly akatanga dambudziko uye akatanga kubheja paTirzepatide kuti atore nzvimbo mumusika wekurasikirwa nehuremu.
Tirzepatide ndeye vhiki nevhiki GIPR/GLP-1R dual agonist, GIP (glucose-inotsamira insulini inosimudzira polypeptide) imwe nhengo yemhuri yeglucagon peptide, ine mhedzisiro yekusimudzira insulin secretion nenzira inotsamira insulini uye inokurudzira glucagon secretion mune hypoglycemic. nyika, GIPR/GLP-1R dual agonist inogona kuburitsa kudzora shuga yeropa, kuonda uye zvimwe zvinokonzeresa nekukurudzira zvese GIP uye GLP-1 nzira dzepasi.Tirzepatide yakabvumidzwa neFDA muna 2022-5 (zita rekutengesa: Mounjaro) kuti ishandiswe pamwe nekudya uye kurovedza muviri kuvandudza glycemic control muvakuru vane Type 2 chirwere cheshuga.
Nguva yekutumira: Sep-18-2023